Immuron Ltd.(NASDAQ : IMRN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Pharmaceuticals Major
|MRK||Merck & Co., Inc.||2.32%||78.94||0.7%||$1567.72m|
|JNJ||Johnson & Johnson||3.07%||165.03||0.7%||$1007.78m|
|BMY||Bristol-Myers Squibb Co.||0.96%||57.49||1.0%||$657.66m|
|LLY||Eli Lilly & Co.||0.86%||241.03||1.1%||$614.58m|
|NVO||Novo Nordisk A/S||1.47%||104.95||0.1%||$91.96m|
|EDSA||Edesa Biotech, Inc.||7.67%||8.33||0.0%||$76.27m|
|CRVS||Corvus Pharmaceuticals, Inc.||3.68%||4.79||0.7%||$58.58m|
Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the following segments: Research and Development, and HyperImmune Products.The Research and Development segment involves the R&D projects performed in Australia, Israel, and United States. The HyperImmune Products segment comprises of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.